Molina Healthcare (MOH) Receives a Sell from Wells Fargo

Wells Fargo analyst Steve Baxter maintained a Sell rating on Molina Healthcare (MOHResearch Report) on January 6 and set a price target of $304.00. The company’s shares closed last Wednesday at $292.08.

According to, Baxter is a 1-star analyst with an average return of -2.2% and a 61.8% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Agilon Health, UnitedHealth, and Oscar Health.

Molina Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $333.83.

See the top stocks recommended by analysts >>

The company has a one-year high of $316.04 and a one-year low of $196.08. Currently, Molina Healthcare has an average volume of 236.4K.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOH in relation to earlier this year. Most recently, in November 2021, Daniel Cooperman, a Director at MOH sold 5,000 shares for a total of $1,545,650.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the Health Plans and Other segments. The Health Plans segment consists of health plans in 11 states and the Commonwealth of Puerto Rico and includes direct delivery business. The Other segment includes the historical results of the MMIS and behavioral health subsidiaries. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Read More on MOH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed